Metric Finance
LearnFAQ
LearnFAQ

Learn / ARGX

NASDAQ: ARGX

Argenx SE (ARGX) stock, explained like you're 5

Argenx SE trades on the Nasdaq under the ticker ARGX. It is a large cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 51.2 billion dollars.

Ticker
ARGX
Exchange
Nasdaq
Sector
Healthcare
Industry
Biological Products (No Diagnostic Substances)
Size
Large cap, about 51.2 billion dollars

Is Argenx SE a small, medium or large cap company?

Yes. Argenx SE is a large cap stock. Its market cap, which is the total value of all its shares, is about 51.2 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Argenx SE makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves ARGX stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • argenx SE (ARGX.BR) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • ARGX Dec 2027 790.000 call (ARGX271217C00790000) Stock Historical Prices & Data (Yahoo! Finance Canada)
  • ARGX Dec 2027 930.000 call (ARGX271217C00930000) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • argenx SE (1AEA.HM) stock price, news, quote and history (Yahoo Finance Australia)
  • ARGX Dec 2027 1580.000 call (ARGX271217C01580000) Stock Price, News, Quote & History (Yahoo! Finance Canada)

Follow ARGX in your daily brief

Each trading day at 5 PM ET we post what happened to Argenx SE and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow ARGX

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Argenx SE stock

What does Argenx SE do?

Argenx SE trades on the Nasdaq under the ticker ARGX. It is a large cap company in the biological products (no diagnostic substances) industry, part of the healthcare sector, with a market value of about 51.2 billion dollars.

What is the ticker symbol for Argenx SE?

Argenx SE trades under the ticker ARGX on the Nasdaq.

What is Argenx SE's market cap?

Argenx SE is a large cap stock with a market cap of about 51.2 billion dollars.

How does Argenx SE make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves ARGX stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow ARGX stock every day?

Add ARGX to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow ARGX daily

A free brief on Argenx SE and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • RVMD · Revolution Medicines
  • BNTX · BioNTech SE
  • EXEL · Exelixis
  • NBIX · Neurocrine Biosciences

Similar stocks

  • RVMDRevolution Medicines
  • BNTXBioNTech SE
  • EXELExelixis
  • NBIXNeurocrine Biosciences

Compare ARGX: ARGX vs RVMD, ARGX vs BNTX, ARGX vs EXEL

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed